Redox-Cycling “Mitocans” as Effective New Developments in Anticancer Therapy
Authors:
- Rumiana BakalovaRBRumiana Bakalova
- Dessislava LazarovaDLDessislava Lazarova
- Akira SumiyoshiASAkira Sumiyoshi
- Sayaka ShibataSSSayaka Shibata
- Zhivko ZhelevZZZhivko Zhelev
- Biliana NikolovaBNBiliana Nikolova
- Severina SemkovaSSSeverina Semkova
- Tatyana VlaykovaTatyana Vlaykova
- Ichio AokiIAIchio Aoki
- Tatsuya HigashiTatsuya Higashi
Open Access
- 8 May 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (9) , 8435
Abstract
Our study proposes a pharmacological strategy to target cancerous mitochondria via redox-cycling “mitocans” such as quinone/ascorbate (Q/A) redox-pairs, which makes cancer cells fragile and sensitive without adverse effects on normal cells and tissues. Eleven Q/A redox-pairs were tested on cultured cells and cancer-bearing mice. The following parameters were analyzed: cell proliferation/viability, mitochondrial superoxide, steady-state ATP, tissue redox-state, tumor-associated NADH oxidase (tNOX) expression, tumor growth, and survival. Q/A redox-pairs containing unprenylated quinones exhibited strong dose-dependent antiproliferative and cytotoxic effects on cancer cells, accompanied by overproduction of mitochondrial superoxide and accelerated ATP depletion. In normal cells, the same redox-pairs did not significantly affect the viability and energy homeostasis, but induced mild mitochondrial oxidative stress, which is well tolerated. Benzoquinone/ascorbate redox-pairs were more effective than naphthoquinone/ascorbate, with coenzyme Q0/ascorbate exhibiting the most pronounced anticancer effects in vitro and in vivo. Targeted anticancer effects of Q/A redox-pairs and their tolerance to normal cells and tissues are attributed to: (i) downregulation of quinone prenylation in cancer, leading to increased mitochondrial production of semiquinone and, consequently, superoxide; (ii) specific and accelerated redox-cycling of unprenylated quinones and ascorbate mainly in the impaired cancerous mitochondria due to their redox imbalance; and (iii) downregulation of tNOX.Keywords
Funding Information
- IC-MedTech Corp., US (#21H04966, #21KK0201, #17KK0102, JPMXS0450400422)
- Japanese Agency for Promotion of Science (#21H04966, #21KK0201, #17KK0102, JPMXS0450400422)
- JST/MEXT (#21H04966, #21KK0201, #17KK0102, JPMXS0450400422)
This publication has 76 references indexed in Scilit:
- Ubiad1 Is an Antioxidant Enzyme that Regulates eNOS Activity by CoQ10 SynthesisCell, 2013
- Features of Idebenone and Related Short-Chain Quinones that Rescue ATP Levels under Conditions of Impaired Mitochondrial Complex IPLOS ONE, 2012
- Capsaicin-Mediated tNOX (ENOX2) Up-regulation Enhances Cell Proliferation and Migration in Vitro and in VivoJournal of Agricultural and Food Chemistry, 2012
- Fermented wheat germ extract - nutritional supplement or anticancer drug?Nutrition Journal, 2011
- Vitamin K3 and vitamin C alone or in combination induced apoptosis in leukemia cells by a similar oxidative stress signalling mechanismCancer Cell International, 2011
- Down-regulation of TERE1/UBIAD1 activated Ras–MAPK signalling and induced cell proliferationCell Biology International Reports, 2010
- Molecular Cloning and Characterization of a Candidate Human Growth-Related and Time-Keeping Constitutive Cell Surface Hydroquinone (NADH) OxidaseBiochemistry, 2008
- DNA polymerase γ inhibition by vitamin K3 induces mitochondria‐mediated cytotoxicity in human cancer cellsCancer Science, 2008
- Alternative Splicing as the Basis for Specific Localization of tNOX, a Unique Hydroquinone (NADH) Oxidase, to the Cancer Cell SurfaceBiochemistry, 2007
- Exposing the Complex III Qo semiquinone radicalBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2007